Therapy involving diabetes drug empagliflozin shows promise in delaying hospitalizations for heart failure
HMN 2024 – About 800,000 people in the U.S. suffer a heart attack every year, and about 30% of them will go on to develop heart failure. There are limited treatments to prevent or slow that development. A large international study led by Duke researchers investigated whether the diabetes drug empagliflozin (marketed under the brand name Jardiance) might […]